iOncologi Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 3

Employees

  • Latest Deal Type
  • Seed

  • Latest Deal Amount
  • $3.25M

  • Investors
  • 3

iOncologi General Information

Description

Operator of a biotechnology company intended to focus on novel immunotherapies for the treatment of refractory cancers and infectious diseases. The company specializes in the use of intravenously delivered stem cells to overcome resistance to immune checkpoint inhibitors and holds particular expertise in the treatment of malignant brain tumors, enabling adult and pediatric patients with malignant gliomas to get advanced immunomodulatory stem cell therapy for speedy recovery.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 2691 Northwest 138th Terrace
  • Gainesville, FL 32606
  • United States
+1 (352)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • 2691 Northwest 138th Terrace
  • Gainesville, FL 32606
  • United States
+1 (352)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

iOncologi Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Seed Round 23-May-2025 $3.25M Completed Clinical Trials - General
2. Accelerator/Incubator Completed Startup
1. University Spin-Out 01-Jan-2017 Completed Startup
To view iOncologi’s complete valuation and funding history, request access »

iOncologi Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

iOncologi Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
ENKORE International Enterprises Venture Capital Minority
University of Florida University
UF Innovate Ventures Accelerator/Incubator
To view iOncologi’s complete investors history, request access »

iOncologi Acquisitions (1)

iOncologi’s most recent deal was a Merger/Acquisition with TargImmune Therapeutics. The deal was made on 14-Mar-2025.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
TargImmune Therapeutics 14-Mar-2025 Merger/Acquisition Drug Discovery
To view iOncologi’s complete acquisitions history, request access »

iOncologi Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
TargImmune Therapeutics Basel, Switzerland 2016

iOncologi FAQs

  • When was iOncologi founded?

    iOncologi was founded in 2017.

  • Where is iOncologi headquartered?

    iOncologi is headquartered in Gainesville, FL.

  • What is the size of iOncologi?

    iOncologi has 3 total employees.

  • What industry is iOncologi in?

    iOncologi’s primary industry is Drug Discovery.

  • Is iOncologi a private or public company?

    iOncologi is a Private company.

  • What is iOncologi’s current revenue?

    The current revenue for iOncologi is .

  • How much funding has iOncologi raised over time?

    iOncologi has raised $3.25M.

  • Who are iOncologi’s investors?

    ENKORE International Enterprises, University of Florida, and UF Innovate Ventures have invested in iOncologi.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process